MedTrace Logo

Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus

NCT04293510 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2020-03-04

No results posted yet for this study

Summary

One of the best understood mechanisms by which cytokines activate signals, thus eliciting specific responses in target cells, involves enzymes such as Janus kinases (JAKs) and transcriptional factors such as signal transducers and activators of transcription (STATs). For immune mediated diseases, both activating and inactivating mutations of JAKs and STATs may cause abnormalities in immune homeostasis. Polymorphisms of JAK/STAT genes have been linked to susceptibility for rheumatoid arthritis (RA) , systemic lupus erythematosus (SLE), psoriatic arthritis (PA) and inflammatory bowel disease (IBD) .

Janus\_kinase 3 expression will be evaluated in the serum and renal tissue of lupus patients during active stage of the disease through this study

Conditions

Interventions

PROCEDURE

renal biopsy and blood sampling

renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
7 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2021-07-15
Completion
2022-07-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04293510 on ClinicalTrials.gov